These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18382352)

  • 1. Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry.
    Capizzi E; Gruppioni E; Grigioni AD; Gabusi E; Grassigli A; Grigioni WF; Fiorentino M
    Diagn Mol Pathol; 2008 Dec; 17(4):220-6. PubMed ID: 18382352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
    López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
    Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative multi-methodological measurement of ERBB2 status in breast cancer.
    Ginestier C; Charafe-Jauffret E; Penault-Llorca F; Geneix J; Adélaïde J; Chaffanet M; Mozziconacci MJ; Hassoun J; Viens P; Birnbaum D; Jacquemier J
    J Pathol; 2004 Mar; 202(3):286-98. PubMed ID: 14991893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder?
    Amsellem-Ouazana D; Bièche I; Molinié V; Elie C; Vieillefond A; Tozlu S; Botto H; Debré B; Lidereau R
    Eur Urol; 2006 Jun; 49(6):1035-42; discussion 1042-3. PubMed ID: 16466848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
    Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C
    Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
    Mrhalová M; Kodet R; Kalinová M; Hilská I
    Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinoma.
    Bossard C; Bieche I; Le Doussal V; Lidereau R; Sabourin JC
    Anticancer Res; 2005; 25(6C):4679-83. PubMed ID: 16334160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values.
    Monego G; Arena V; Maggiano N; Costarelli L; Crescenzi A; Zelano G; Amini M; Capelli A; Carbone A
    Scand J Clin Lab Invest; 2007; 67(4):402-12. PubMed ID: 17558895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry.
    Pellegrini C; Falleni M; Marchetti A; Cassani B; Miozzo M; Buttitta F; Roncalli M; Coggi G; Bosari S
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3645-52. PubMed ID: 14506153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.
    Sáez A; Andreu FJ; Seguí MA; Baré ML; Fernández S; Dinarés C; Rey M
    Breast; 2006 Aug; 15(4):519-27. PubMed ID: 16290155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.
    Kim MA; Jung EJ; Lee HS; Lee HE; Jeon YK; Yang HK; Kim WH
    Hum Pathol; 2007 Sep; 38(9):1386-93. PubMed ID: 17555797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
    Barberis M; Pellegrini C; Cannone M; Arizzi C; Coggi G; Bosari S
    Am J Clin Pathol; 2008 Apr; 129(4):563-70. PubMed ID: 18343783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
    Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B
    Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: a comparative methodological study using the Ventana BenchMark automated staining system and manual tests.
    Bánkfalvi A; Boecker W; Reiner A
    Int J Oncol; 2004 Oct; 25(4):929-35. PubMed ID: 15375542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of silver-enhanced in situ hybridization for evaluating HER2 gene status in invasive breast carcinoma: a comparative study.
    Lee Y; Ryu Y; Jeong H; Chang H; Kim Y; Kim A
    Arch Med Res; 2012 Feb; 43(2):139-44. PubMed ID: 22475781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.